VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention following a research report highlighting its AI-powered drug toxicity platform and growing FDA momentum behind human-relevant New Approach Methodologies (NAMs). The company’s NAMkind™ 3D human liver and intestinal tissue models have reported approximately 91% predictive accuracy for liver toxicity and up to 96% accuracy predicting drug-induced diarrhea, while commercialization is expanding through initial China contracts and APAC distribution relationships. VivoSim has reiterated guidance for 500%+ fiscal 2027 revenue growth from its NAM-based contract research business and recently reported approximately $10.1 million in cash, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested inflammatory bowel disease program. VivoSim has stated it remains eligible for up to an additional $45 million in potential milestone payments if specified development and commercial milestones are achieved.
VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liver toxicology capabilities. VivoSim Labs to Add Rat Liver Model to NAMkind Platform
VivoSim Labs, Inc. (NASDAQ: VIVS) (“VivoSim” or the “Company”) unveils new clinical benchmark data at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria, demonstrating the ability of its NAMkind™ 3D human liver and intestinal platforms to predict drug toxicity across small molecules and increasingly complex therapies, including Antibody-Drug Conjugates (ADCs). VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at
VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today celebrated the U.S. Food and Drug Administration's (FDA) direct final rule updating its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use. VivoSim Labs Celebrates Updated FDA Regulations Allowing
VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety and efficacy, VivoSim Labs Extends NAMkind Platform with Human Disease
VivoSim Labs, Inc. (Nasdaq: VIVS) and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim’s NAMkind™ 3D human liver and intestine models show which ones are safe to advance, in weeks rather than years VivoSim Labs and Chemveda Life Sciences Join Forces to Put
